Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPharmaxis Ltd

Pharmaxis Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2024-03-12T06:45:07.451003Z
Market Cap
19.51M

Momentum Score

…

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.02
Low
0.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
11.89M
Revenue Per Share
0.02
Gross Profit TTM
7.77M
Debt / Equity
0.21
ROE
-237.24%
Net Debt
-7.19M
ROCE
-69.64%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -11.36M -1.94M -2.97M -13.94M -20.06M
Net income -11.36M -1.94M -2.97M -13.94M -20.30M
Selling general administrative 15.52M 14.08M 14.87M 14.46M 15.49M
Selling and marketing expenses 0.30M 0.76M 1.47M 1.35M 1.14M
Gross profit 3.06M -2.53M 0.74M -0.77M 5.68M
Reconciled depreciation 1.85M 3.24M 3.15M 3.24M 2.62M
Ebit -11.14M -15.39M -2.60M -21.47M -19.82M
Ebitda -9.29M -12.15M 0.55M -18.23M -17.20M
Depreciation and amortization 1.85M 3.24M 3.15M 3.24M 2.62M
Operating income -11.86M -14.44M -3.70M -15.88M -19.82M
Other operating expenses 30.56M 17.42M 26.22M 29.08M 31.56M
Interest expense 0.22M 13.46M 0.37M 0.37M 0.24M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.39M 0.16M 0.57M 1.52M 1.58M
Net interest income -0.11M 13.61M -0.32M 2.52M 0.67M
Income tax expense 14.26M -6.24M 18.36M -2.52M 0.24M
Total revenue 5.76M 7.43M 6.68M 7.03M 5.68M
Total operating expenses 28.35M 30.19M 27.32M 28.49M 31.56M
Cost of revenue 2.71M 9.95M 5.93M 7.80M 1.37M
Total other income expense net 14.03M 7.22M 17.99M 5.00M -0.24M
Net income from continuing ops -11.36M -1.94M -2.97M -13.94M -20.06M
Net income applicable to common shares -11.36M -1.93M -2.97M -13.94M -20.06M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 24.03M 25.19M 33.59M 35.42M 52.67M
Intangible assets 0.68M 1.02M 1.11M 0.94M 0.76M
Other current assets 0.33M 0.32M 0.22M 0.16M 0.14M
Total liab 14.47M 14.38M 30.75M 33.98M 37.85M
Total stockholder equity 9.56M 10.80M 2.85M 1.43M 14.81M
Other current liab 3.47M 0.26M 1.02M 0.48M 1.11M
Common stock 389.70M 380.44M 371.37M 367.30M 367.30M
Capital stock 389.70M 380.44M 371.37M 367.30M 367.30M
Retained earnings -404.45M -393.09M -391.16M -388.19M -374.24M
Other liab 6.43M 8.63M 18.57M 20.84M 23.77M
Other assets 2.82M 2.56M 0.94M 1.08M 1.07M
Cash 9.23M 8.94M 18.71M 14.76M 31.12M
Cash and equivalents 5.98M 2.50M 9.25M 2.70M 2.65M
Total current liabilities 8.03M 6.10M 7.89M 6.83M 8.11M
Current deferred revenue 0.94M 3.19M 3.60M 2.75M 3.60M
Net debt -7.19M -4.65M -12.39M -6.61M -23.95M
Short term debt 2.04M 2.03M 2.03M 1.83M 1.20M
Short long term debt total 2.04M 4.29M 6.32M 8.15M 7.17M
Other stockholder equity 24.31M 23.46M 22.64M 22.32M 21.76M
Property plant equipment 1.84M 3.21M 6.23M 8.91M 10.26M
Total current assets 18.68M 19.23M 25.31M 24.49M 40.58M
Net tangible assets 8.88M 10.80M 1.73M 0.49M 14.06M
Short term investments 2.77M 6.00M 8.53M 11.31M 28.33M
Net receivables 7.48M 7.64M 2.74M 6.94M 7.19M
Long term debt - - - - 7.17M
Inventory 1.64M 2.34M 3.64M 2.63M 2.12M
Accounts payable 1.58M 0.61M 1.24M 1.76M 2.20M
Accumulated other comprehensive income 24.31M 23.46M 22.64M 22.32M 21.76M
Common stock total equity - - - 367.30M 367.30M
Non currrent assets other -2.52M -4.24M -7.34M -9.85M 1.07M
Non current assets total 5.35M 5.95M 8.28M 10.92M 12.09M
Capital lease obligations 2.04M 4.29M 6.32M 8.15M 7.17M
Long term debt total 0.00M 2.26M 4.29M 6.32M 5.97M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.13M -0.31M -0.64M -0.57M -0.98M
Change to liabilities 1.08M -0.62M -0.52M -0.44M 0.07M
Total cashflows from investing activities -0.13M -0.14M -0.64M -0.57M -0.98M
Net borrowings -2.25M -2.38M -2.31M -2.23M -1.59M
Total cash from financing activities 6.98M 6.63M 1.52M -2.50M 20.83M
Change to operating activities -2.10M -5.14M 5.22M -0.33M -6.02M
Net income -11.36M -1.94M -2.97M -13.94M -20.30M
Change in cash 0.29M -9.78M 3.95M -16.36M 0.05M
Begin period cash flow 8.94M 18.71M 14.76M 31.12M 31.07M
End period cash flow 9.23M 8.94M 18.71M 14.76M 31.12M
Total cash from operating activities -7.28M -16.30M 3.07M -13.28M -19.80M
Issuance of capital stock 10.00M 9.74M 4.37M - 24.00M
Depreciation 1.81M 3.12M 3.03M 3.12M 2.62M
Other cashflows from investing activities - -0.14M -0.64M -0.57M -0.57M
Change to inventory 0.70M 1.30M -1.01M -0.51M 0.28M
Change to account receivables 0.27M -1.41M 0.29M -0.29M 0.62M
Sale purchase of stock -0.74M -0.67M -0.30M -0.30M 24.00M
Other cashflows from financing activities -2.28M -2.44M -2.54M -2.50M -3.17M
Change to netincome 2.29M -17.60M -1.09M -1.01M 2.46M
Capital expenditures 0.14M 0.31M 0.65M 0.57M 0.98M
Change in working capital 0.96M -0.11M -0.72M -0.80M 0.90M
Stock based compensation 0.82M 0.82M 0.32M 0.56M -
Other non cash items 2.27M -17.49M 3.01M -2.47M 17.44M
Free cash flow -7.42M -16.61M 2.42M -13.86M -0.98M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AFP
Aft Pharmaceuticals Ltd		 -0.04
1.11%		 3.55 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 -0.06
2.22%		 2.64 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 -0.00
1.72%		 0.06 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 0.01
3.75%		 0.41 40.00 166.67 1.06 0.79 0.57 7.45

Profile*

Pharmaxis Ltd

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Pax World Funds Series Trust I

800-372-7827

https://www.pharmaxis.com.au

70

Name Title Year Born
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Sec. 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin Head of Medical & Regulatory Affairs - Alliance Management 1972
Dr. Jana Baskar Chief Medical Officer NA
Mr. Cameron David Billingsley Gen. Counsel 1977
Dr. Dieter Hamprecht Head of Chemistry for Drug Discovery NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…